🔎 Trials Near Me

Utama › Karsinoma Epitel Ovari › Tennessee

Kajian klinikal Karsinoma Epitel Ovari di Tennessee

6 kajian untuk Karsinoma Epitel Ovari sedang mencari peserta di lokasi di Tennessee.

Bandar di Tennessee

Teks kajian rasmi (Bahasa Inggeris)

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Erlanger Health, Chattanooga
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 15 Sep 2026 · NCT06915025

Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer

  • University of Tennessee Medical Center - Knoxville, Knoxville
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Wanita · Dikemas kini 17 Ogo 2026 · NCT07764133

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  • Research Site, Germantown
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 21 Jul 2026 · NCT07218809

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Sarah Cannon Research Institute (Oncology Associates of Oregon PC), Nashville
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 2 Jul 2026 · NCT06819007

CT-95 in Advanced Cancers Associated With Mesothelin Expression

  • Context Investigational Site, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT06756035

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  • Vanderbilt University Medical Center, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Ogo 2025 · NCT04429542

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.